The 2017 American Society of Clinical Oncology (ASCO) Annual Meeting was held June 2 – 6 at McCormick Place in Chicago, Illinois.

Photo by © ASCO/Scott Morgan 2017

Large MM trial finds denosumab non-inferior to ZA for SRE

Attendees at ASCO 2017
Annual Meeting
Photo © ASCO/Scott Morgan 2017
The largest international multiple myeloma (MM) trial ever conducted, according to the trial sponsor, met its primary endpoint, demonstrating that denosumab is non-inferior to zoledronic acid (ZA) in delaying the time to first on-study skeletal-related event (SRE) in patients with MM. In addition to bone-specific... [Read Article]

Neurotoxicity needs separate treatment from CRS in CAR T-cell therapy

Attendees during Plenary Session at ASCO Annual Meeting 2017
Photo © ASCO/Todd Buchanan 2017
The neurotoxicity in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL) treated with CD19 CAR T cells is a separate process from cytokine release syndrome (CRS) and needs to be treated separately, according to a new study... [Read Article]

CAR T cells plus ibrutinib induce CLL remissions

Poster session at ASCO 2017
Photo © ASCO/David Eulitt 2017
Chimeric antigen receptor (CAR) T cells combined with ibrutinib enhance T-cell function and can induce complete remission (CR) in patients with chronic lymphocytic leukemia (CLL), researchers report. Many CLL patients receive ibrutinib treatment, which is well tolerated, but few patients achieve CR. Immunotherapy with anti-CD19... [Read Article]

‘Admirable’ overall survival attainable in AML with enasidenib

McCormick Place during
ASCO 2017 Annual Meeting
Photo © ASCO/Danny Morton 2017
The experimental mutant IDH2 (mIDH2) inhibitor enasidenib has produced “admirable” overall survival in patients with mIDH2 relapsed or refractory acute myeloid leukemia (AML), according to Eytan M. Stein, MD, an investigator on the phase 1 dose escalation and expansion study. Patients who achieved... [Read Article]

Combo with daratumumab could be alternative to ASCT in MM

Attendees at ASCO 2017 Annual Meeting
Photo © ASCO/Scott Morgan 2017
Results of an open-label phase 1b study of daratumumab combined with carfilzomib, lenalidomide, and dexamethasone (KRd) in newly diagnosed multiple myeloma (MM) patients have shown the combination to be highly effective, with an overall response rate of 100%. Ninety-one percent of patients achieved a... [Read Article]

Deep molecular responses achievable in AML pts treated with gilteritinib

Lobby of McCormick Place during ASCO 2017
Photo © ASCO/Danny Morton 2017
Next generation sequencing (NGS) has shown that the FLT3 inhibitor gilteritinib can produce deep molecular responses in a subset of patients with acute myeloid leukemia (AML), according to new research. Gilteritinib is a highly selective FLT3/AXL inhibitor that is active against FLT3-ITD and... [Read Article]

Majority of AML patients do not receive recommended molecular genetic testing

DNA helices
Image courtesy of the
National Institute of
General Medical Sciences
While 67% of newly diagnosed patients with acute myeloid leukemia (AML) receive some genetic testing, only 9% receive all 7 of the genetic tests recommended by the National Comprehensive Cancer Network (NCCN), according to new research. The data comes from the CONNECT MDS/AML... [Read Article]

Dasatinib potentially a new SOC for children with CML-CP, study author suggests

Child with cancer
Photo by Bill Branson
The largest ongoing and prospective trial of pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP), according to the best knowledge of the investigators, has found dasatinib to be safe and effective as first- or second-line therapy for these children. Patients refractory to or intolerant of imatinib... [Read Article]

Pembrolizumab enhances CAR T-cell persistence in relapsed ALL

McCormick Place during
ASCO 2017 Annual Meeting
Photo © ASCO/Danny Morton 2017
Three of 6 pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) whose CD19 chimeric antigen receptor (CAR) T cells did not persist even after reinfusion demonstrated persistence when the PD-1 checkpoint inhibitor pembrolizumab was added to the regimen. CAR T... [Read Article]

Addition of ublituximab to ibrutinib improves response in r/r CLL

McCormick Place during
ASCO 2017 Annual Meeting
Photo © ASCO/Danny Morton 2017
Ibrutinib, the Bruton’s tyrosine kinase (BTK) inhibitor, has transformed the treatment landscape for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). Yet for patients with high-risk molecular features, such as 11q deletion, 17p deletion, or TP53 mutation, relapse remains problematic. Investigators... [Read Article]